Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
Completed · Phase 1
Conditions studied: Atherosclerosis
In brief
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.
Key facts
- Study ID
- NCT00411073
- Run by
- GlaxoSmithKline
- People needed
- 72
- Starts
- 2006-12-01
- Last updated by the study team
- 2016-10-28
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy
- Body weight greater than 50 kg (110 lbs) and a body mass index between 19 and 30
- Signed and dated written informed consent prior to admission to the study
- Subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
You may not qualify if…
- cardiac abnormalities
- history of asthma or severe allergic reactions
- history of alcohol or drug abuse
- use of prescription or non-prescription drugs or vitamins or herbal supplements
- history of cholecystectomy or biliary tract disease
- pregnant or nursing women
- history of allergy to the study drugs
Where it is running
- GSK Investigational Site — Evansville, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.